<DOC>
	<DOC>NCT02391051</DOC>
	<brief_summary>This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.</brief_summary>
	<brief_title>Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial</brief_title>
	<detailed_description>Patients with low-risk prostate cancer will receive HDR-Brachytherapy: 2 x 13,5 Gy.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age &gt; 18 Histologically confirmed prostate cancer Gleason Score of index lesion ≤ 6 (3+3) Tumor stage: cT12a cN0 cM0 Unilateral affection; index lesion ≤ 0.5ml with or without clinically nonsignificant lesion contralateral. No more than 25% of the punch should be affected. Therefore a 3DTPMbiopsy is mandatory before treatment. PSA ≤ 10/ng/ml Prostate volume &lt; 60 m^3 No distant metastasis Life expectancy &gt; 10 years Informed consent Tumor stage ≥ T2b Known metastasis: N+ and/or M1 General anesthesia or peridural anesthesia is not possible Coagulation disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>focal brachytherapy</keyword>
	<keyword>PSA</keyword>
	<keyword>Biological marker</keyword>
</DOC>